NIA R01: Drug Repositioning and Combination Therapy for Alzheimer's Disease
Funds researchers combining computational and experimental approaches to test repositioned drugs for Alzheimer's disease treatment through NIH R01 grants.
The National Institute on Aging (NIA), part of the National Institutes of Health (NIH) under the Department of Health and Human Services, administers this R01 grant through the PAR-25-374 Notice of Funding Opportunity (NOFO). It sits under the ACTDRx AD (Advancing Combination Therapy and Drug Repurposing for Alzheimer's Disease) program, a cross-disciplinary initiative using translational bioinfor…
Translational bioinformatics and preclinical experimental work to identify and test drugs (individually or in combination) that may treat Alzheimer's disease and related dementias. Includes PK/PD modeling, mouse models, cell-based models, iPSCs, organoids, and non-pharmacologic interventions.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up